奈普利溶素抑制对接受靶剂量肾素-血管紧张素系统抑制剂的2型糖尿病合并慢性心力衰竭患者肾功能的影响:PARADIGM-HF试验的二次分析
PARADIGM-HF试验的二次意向治疗分析纳入8399例轻中度慢性心力衰竭伴收缩功能障碍患者,比较沙库巴曲/缬沙坦(97mg/103mg每日两次)与依那普利(10mg每日两次)对44个月随访期间eGFR变化的影响。结果显示,沙库巴曲/缬沙坦组eGFR下降速率较依那普利组更慢(-1.3 vs -1.8 mL/min per 1.73 m2 per year;p<0.0001),且糖尿病患者的获益幅度大于无糖尿病患者(差值0.6 vs 0.3 mL/min per 1.73 m2 per year;pinteraction=0.038)。
要点
- 无糖尿病患者eGFR年下降1.1 mL/min per 1.73 m2,糖尿病患者下降2.0 mL/min per 1.73 m2(p<0.0001)。
- 沙库巴曲/缬沙坦组eGFR下降速率较依那普利组更慢(-1.3 vs -1.8 mL/min per 1.73 m2 per year;p<0.0001)。
- 糖尿病患者的获益幅度大于无糖尿病患者(差值0.6 vs 0.3 mL/min per 1.73 m2 per year;pinteraction=0.038)。
核心结论
- 在肾素-血管紧张素系统已被最大程度阻断的患者中,加用奈普利溶素抑制可减弱糖尿病加速慢性心力衰竭患者肾功能恶化的效应。
研究设计与样本
- 随机双盲PARADIGM-HF试验的二次意向治疗分析,纳入8399例轻中度慢性心力衰竭伴收缩功能障碍患者,其中糖尿病3784例、无糖尿病4615例,随访44个月。
主要发现
- 无糖尿病患者eGFR年下降1.1 mL/min per 1.73 m2(95% CI 1.0-1.2),糖尿病患者下降2.0 mL/min per 1.73 m2(95% CI 1.9-2.1)(p<0.0001)。
- 与依那普利组相比,沙库巴曲/缬沙坦组eGFR下降速率更慢(-1.3 vs -1.8 mL/min per 1.73 m2 per year;p<0.0001)。
- 沙库巴曲/缬沙坦的获益幅度在糖尿病患者中大于无糖尿病患者(差值0.6 mL/min per 1.73 m2 per year [95% CI 0.4-0.8] vs 0.3 mL/min per 1.73 m2 per year [95% CI 0.2-0.5];pinteraction=0.038)。
- 奈普利溶素抑制在糖尿病患者中更大的效应不能由治疗对心力衰竭病程或HbA1c的影响解释。
- 当eGFR变化经尿环磷酸鸟苷调整后,沙库巴曲/缬沙坦在糖尿病患者中的额外获益不再明显(p=0.41)。
关键数值与推荐
- 沙库巴曲/缬沙坦剂量为97mg/103mg每日两次,依那普利剂量为10mg每日两次。
- eGFR下降速率以mL/min per 1.73 m2 per year表示。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neprilysin inhibition has favourable effects on experimental diabetic nephropathy. We sought to assess the effects of neprilysin inhibition on the course of renal function in patients with type 2 diabetes. METHODS: In the randomised, double-blind PARADIGM-HF trial, the effects of sacubitril/valsartan (97 mg/103 mg twice daily) were compared with enalapril (10 mg twice daily) in 8399 patients with mild-to-moderate chronic heart failure and systolic dysfunction. In this secondary intention-to-treat analysis, we assessed the change in estimated glomerular filtration rate (eGFR) over a 44-month follow-up period in patients with (n=3784) and those without (n=4615) diabetes. PARADIGM-HF is registered with ClinicalTrials.gov, number NCT01035255. FINDINGS: eGFR decreased by 1·1 mL/min per 1·73 m2 per year (95% CI 1·0-1·2) in patients without diabetes, but by 2·0 mL/min per 1·73 m2 per year (1·9-2·1) in those with diabetes (p<0·0001). Compared with patients treated with enalapril, those treated with sacubitril/valsartan had a slower rate of decline in eGFR (-1·3 vs -1·8 mL/min per 1·73 m2 per year; p<0·0001), and the magnitude of the benefit was larger in patients with versus those without diabetes (difference 0·6 mL/min per 1·73 m2 per year [95% CI 0·4-0·8] in patients with vs 0·3 mL/min per 1·73 m2 per year [0·2-0·5] in those without diabetes; pinteraction=0·038). The greater effect of neprilysin inhibition in patients with diabetes could not be explained by the effects of treatment on the course of heart failure or on HbA1c. The incremental benefit of sacubitril/valsartan in patients with diabetes was no longer apparent when changes in eGFR were adjusted for urinary cyclic guanosine monophosphate (p=0·41). INTERPRETATION: In patients in whom the renin-angiotensin system is already maximally blocked, the addition of neprilysin inhibition attenuates the effect of diabetes to accelerate the deterioration of renal function that occurs in patients with chronic heart failure. FUNDING: Novartis.
引用
- Packer M, Claggett B, Lefkowitz MP, et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018. PMID: 29661699. doi:10.1016/S2213-8587(18)30100-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。